Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Alcon Japan, Kyowa Kirin Adjust Shipments of Anti-Allergy Drugs
March 19, 2013
- Daiichi Sankyo to File Prasugrel for Cardiovascular Disease in PCI Patients in Japan
March 19, 2013
- Pfizer Japan Launches OAB Treatment Toviaz
March 19, 2013
- Generic Companies Increasing Focus on Fast-growing Oncology Market; Shift to Overseas Production Will Spur Cost Competition
March 18, 2013
- Eisai Appoints Its First Female Executive
March 18, 2013
- MHLW Lifts All-Case Surveillance for Novartis' Lucentis
March 18, 2013
- Nihon Pharmaceutical Industry Voluntarily Recalls Revinbace Tablets 10 mg, Temporarily Suspends Sales
March 18, 2013
- Eisai Eyes Sales of 50 Billion Yen in Asian Generic Biz within 5 Years
March 15, 2013
- Shionogi, Kyoto University to Collaborate on Research for AD Treatment
March 15, 2013
- Eli Lilly Japan Files Tadalafil for BPH, 3rd NDA for Same API
March 15, 2013
- Astellas Files NDA in Japan for SGLT-2 Inhibitor Ipragliflozin
March 15, 2013
- API Corporation to Establish Production Base for Drug Substances, Intermediates in India
March 15, 2013
- Astellas Grants US Firm Global Rights to Ceftolozane
March 14, 2013
- Eli Lilly Japan’s 2012 Sales Surge 10% on Brisk Zyprexa; NHI Price Cut Countered
March 14, 2013
- Sanofi Japan Aims to Enhance Leadership Status in Diabetes Sector with GLP-1, President Says
March 14, 2013
- A Number of Blockbuster Candidates Emerging from Japanese Pharmas’ In-house R&D: Dr Nakamura of Pharma Forum Institute
March 14, 2013
- Astellas, Ambit to Terminate Development Collaboration for FLT3 Kinase Inhibitors
March 14, 2013
- Biosimilar Makers Getting Premium-Linked Inquiries from Medical Institutions
March 13, 2013
- Overseas Business Making Up for Sluggish Domestic Market; Weaker Yen Could Add Further Boost in 4th Quarter
March 13, 2013
- CSOs Diversifying Services in Japan amid Increasing Use of CMRs
March 12, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…